Las Vegas(KLAS)-TV Personality, Peter Madrigal, has launched ‘Reality Network’ providing a one stop shop for all things ...

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

Learn insights from Madrigal Pharmaceuticals' Q2 2025 earnings: Rezdiffra's growth, new patent till 2045, global expansion, and pipeline advances.

Madrigal (MDGL) delivered earnings and revenue surprises of +45.40% and +32.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Tuesday reported a loss of $42.3 million in its second quarter. The West Conshohocken, ...

Representatives from four Utah entities received the Tonahuac Award from the Federation of United Mexicans in Utah for their ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

Prosecutors continued urging a court to release some of those records in the criminal case-turned-political fireball.

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

CEO touts 'amazing' sales success of new drug, but firm's stock slumps Montco firm's shares soar on huge sales increase of ...

The US congressional committee investigating convicted sex offender Jeffrey Epstein has issued subpoenas for a number of high ...